TrialLancet (London, England)2017

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Paul M Ridker et al.PubMed ↗Publisher ↗

No numbers read from the abstract.